Paper Details

  1. Home
  2. Paper Details

Parkinson's disease: Cogentin with Sinemet, a better response.

Author: GildenE R, HanschE C, HirschS B, PotvinA R, PotvinJ H, SyndulkoK, TourtellotteW W

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Benztropine mesylate (Cogentin) was evaluated as an adjuvant to levadopa-carbidopa (Sinemet) in 29 patients with Parkinson's disease. The combination of Sinemet and benztropine resulted in significantly greater improvement than Sinemet alone, as indicated by both clinician and patient assessments. Benztropine improved rigidity, finger tapping speed, and activities of daily living. No significant side effects were observed.
Paper Details　
Original Abstract of the Article :
1. A randomized, placebo controlled, double-blind cross-over study was conducted to evaluate the clinical efficacy of the anticholinergic agent, benztropine mesylate (CogentinR) in 29 patients with mild to moderate, idiopathic Parkinson disease. 2. Patients were maintained on a stable, therapeutical...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0364-7722(82)80107-0

データ提供：米国国立医学図書館（NLM）

Sinemet Plus Cogentin: A Better Response for Parkinson's Disease

This double-blind, randomized, cross-over study investigated the effectiveness of adding the anticholinergic agent benztropine mesylate (Cogentin) to levodopa-carbidopa (Sinemet) in patients with Parkinson's disease. The researchers evaluated the clinical efficacy of the combined treatment in 29 patients with mild to moderate, idiopathic Parkinson's disease, assessing neurological functions and patient-reported outcomes. Their findings suggest that the addition of Cogentin to Sinemet may provide significant improvements in symptom management.

Cogentin's Added Value

The study showed that Sinemet plus Cogentin resulted in significantly greater improvements in overall treatment efficacy compared to Sinemet plus placebo. The combination therapy demonstrated statistically significant improvements in rigidity, finger tapping speed, and activities of daily living. These findings suggest that Cogentin may offer a valuable adjunct to Sinemet treatment.

Managing Parkinson's Symptoms

This study provides insights into the potential benefits of combining Sinemet with Cogentin for Parkinson's disease management. It highlights the importance of exploring various treatment options to optimize symptom control and improve quality of life for patients.

Dr.Camel's Conclusion

Like a camel navigating a challenging desert terrain, finding the right combination of treatments can help manage Parkinson's symptoms effectively. This study suggests that adding Cogentin to Sinemet can lead to significant improvements in neurological function and overall well-being for patients.

Date :
  1. Date Completed 1982-10-21
  2. Date Revised 2019-09-09
Further Info :

Pubmed ID

7202230

DOI: Digital Object Identifier

10.1016/s0364-7722(82)80107-0

Related Literature

Article Analysis
・Side Effects of benztropine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.